Screening and identification of compounds inhibiting transcriptional activity of HBV core promoter

Yuxue SUN; Xiafei WEI; Jie LI; Jing CUI; Yuwei WANG; Jieli HU

doi:10.16016/j.1000-5404.202101014

您当前的位置：

首页 >

文章列表页 >

Screening and identification of compounds inhibiting transcriptional activity of HBV core promoter

Basic Medicine | 更新时间：2026-01-09

- Screening and identification of compounds inhibiting transcriptional activity of HBV core promoter
- Journal of Third Military Medical University Vol. 43, Issue 13, Pages: 1192-1203(2021)
- 作者机构：
  
  1.400016 重庆, 重庆医科大学感染性疾病分子生物学教育部重点实验室
  2.400021 重庆, 重庆市中医院检验科，重庆市中医院感染性疾病中西医结合诊治实验室
- 作者简介：
- 基金信息：
  
  the National Natural Science Foundation of China(81871635);the General Program of Natural Science Foundation of Chongqing(cstc2020jcyj-msxmX0764);the Xinglin Scholar Research Project of Chengdu University of TCM(YYZX2019067)
- DOI：10.16016/j.1000-5404.202101014
  CLC： R373.21;R965.1;R978.7
- Received：04 January 2021，
  
  Revised：2021-03-24，
  
  Published：15 July 2021
- 稿件说明：
移动端阅览
Yuxue SUN, Xiafei WEI, Jie LI, et al. Screening and identification of compounds inhibiting transcriptional activity of HBV core promoter[J]. Journal of Third Military Medical University, 2021, 43(13): 1192-1203.
DOI：

Yuxue SUN, Xiafei WEI, Jie LI, et al. Screening and identification of compounds inhibiting transcriptional activity of HBV core promoter[J]. Journal of Third Military Medical University, 2021, 43(13): 1192-1203. DOI： 10.16016/j.1000-5404.202101014.

摘要

目的

构建靶向核心启动子转录的稳定细胞系，筛选影响乙型肝炎病毒(hepatitis B virus，HBV)转录的药物。

方法

利用HepG2细胞，以重组慢病毒的方式构建由HBV核心启动子驱动的Gaussia荧光素酶稳定表达细胞系(HepG2-Pcore-Gluc)。通过检测荧光素酶活性来反映核心启动子的活性变化情况。在HBV复制细胞模型中，通过Southern blot、荧光定量PCR等进一步评估经多轮筛选得到的化合物对HBV RNA、HBV DNA的影响。

结果

利用HepG2-Pcore-Gluc细胞模型筛选1 450种小分子化合物，第1轮筛选到41种化合物，能影响荧光素酶活性2倍以上。将这41种化合物进行第2轮剂量依赖性测试，得到2种化合物: 逆转素(Reversine)、SCH58261。进一步验证发现: Reversine在瞬时转染HBV1.3倍体的HepG2和HepG2.2.15细胞中，能够有效降低HBV RNA、HBV DNA以及HBeAg、HBsAg的水平。

结论

建立了一种新型、高效的抗乙肝药物筛选细胞模型(HepG2-Pcore-Gluc)，利用该模型筛选到一种新型分子Reversine，该分子可以通过抑制HBV核心启动子的转录活性来抑制HBV RNA的转录。

Abstract

Objective

To construct a stable cell line targeting the transcriptional activity of core promoter for screening drugs that affect the transcription of HBV.

Methods

HepG2-Pcore-Gluc was constructed by recombinant lentivirus to stably express Gaussia luciferase driven by HBV core promoter in HepG2 cells

and then the luciferase was detected to indicate the activity of the core promoter. Southern blotting

fluorescence quantitative PCR and other experiments were used to further evaluate the effects of the screened compounds on the levels of HBV RNA and HBV DNA after several rounds of screening in HBV-replication cell models.

Results

Forty-one compounds that could affect luciferase activity larger than 2 times were screened out of 1 450 compounds in the first round screening by using HepG2-Pcore-Gluc cell model

which were tested in a second round of dose-dependent test to produce 2 compounds: Reversine and SCH58261. Further

Reversine effectively decreased the levels of HBV RNA

HBV DNA

HBeAg and HBsAg in transiently-transfected HepG2 and HepG2.2.15 cells.

Conclusion

Reversine is identified by using a novel cell model (HepG2-Pcore-Gluc) which targets the transcription of HBV core promoter. These results provide evidences that Reversine acts through inhibiting the transcriptional activity of core promoter.

关键词

Keywords

references

ARENDS J E, LIEVELD F I, AHMAD S, et al . New viral and immunological targets for hepatitis B treatment and cure: a review[J ] . Infect Dis Ther, 2017, 6(4): 461-476. DOI:10.1007/s40121-017-0173-y.

MARTINEZ M G, VILLERET F, TESTONI B, et al . Can we cure hepatitis B virus with novel direct-acting antivirals?[J ] . Liver Int, 2020, 40(17): 27-34. DOI:10.1111/liv.14364.

TERRAULT N A, LOK A S F, MCMAHON B J, et al . Update on prevention, diagnosis, and treatment of chronic hepatitisB: AASLD 2018 hepatitis B guidance[J ] . Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.

CHENG Z, ZHI X, SUN G, et al . Sodium selenite suppresses hepatitis B virus transcription and replication in human hepatoma cell lines[J ] . J Med Virol, 2016, 88(4): 653-663. DOI:10.1002/jmv.24366.

KÖSE Ș, TATLI KIȘ T, ATALAY S. Efficacy of tenofovir and entecavir in patients who relapsed after pegylated interferon therapy[J]. J Chemother, 2019, 31(4): 209-213. DOI:10.1080/1120009x.2019.1597420.

ANDERSON R T, LIM S G, MISHRA P, et al . Challenges, considerations, and principles to guide trials of combination therapies for chronic hepatitis B virus[J ] . Gastroenterology, 2019, 156(3): 529-533 e4. DOI: 10.1053/j.gastro.2018.11.062.

SUNG J J, WONG M L, BOWDEN S, et al . Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy[J ] . Gastroenterology, 2005, 128(7): 1890-1897. DOI: 10.1053/j.gastro.2005.03.009.

WERLE-LAPOSTOLLE B, BOWDEN S, LOCARNINI S, et al . Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[J ] . Gastroenterology, 2004, 126(7): 1750-1758. DOI: 10.1053/j.gastro.2004.03.018.

WEI Z Q, ZHANG Y H, KE C Z, et al . Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation[J ] . World J Gastroenterol, 2017, 23(34): 6252-6260. DOI:10.3748/wjg.v23.i34.6252.

DENG J J, KONG K E, GAO W W, et al . Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription[J ] . Biochim Biophys Acta Gene Regul Mech, 2017, 1860(4): 491-501. DOI:10.1016/j.bbagrm.2017.02.007.

ZHANG Y, LOU C, XU Y, et al . Screening of inhibitors against histone demethylation jumonji domain-containing protein 3 by capillary electrophoresis[J ] . J Chromatogr A, 2020, 1613: 460625. DOI:10.1016/j.chroma.2019.460625.

NASSAL M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J]. Gut, 2015, 64(12): 1972-1984. DOI:10.1136/gutjnl-2015-309809.

SANJANA N E, SHALEM O, ZHANG F. Improved vectors and genome-wide libraries for CRISPR screening[J]. Nat Methods, 2014, 11(8): 783-784. DOI:10.1038/nmeth.3047.

WEI X F, GAN C Y, CUI J, et al . Identification of compounds targeting hepatitis B virus core protein dimerization through a split luciferase complementation assay[J ] . Antimicrob Agents Chemother, 2018, 62(12). DOI: 10.1128/AAC.01302-18.

QUARLERI J. Core promoter: a critical region where the hepatitis B virus makes decisions[J]. World J Gastroenterol, 2014, 20(2): 425-435. DOI:10.3748/wjg.v20.i2.425.

KRAMVIS A, KEW M C. The core promoter of hepatitis B virus[J]. J Viral Hepat, 1999, 6(6): 415-427. DOI:10.1046/j.1365-2893.1999.00189.x.

LIU C J, KAO J H. Genetic variability of hepatitis B virus and response to antiviral therapy[J]. Antivir Ther, 2008, 13(5): 613-624.

RAMIÈRE C, SCHOLTÈS C, DIAZ O, et al . Transactivation of the h epatitis B virus core promoter by the nuclear receptor FXRalpha[J ] . J Virol, 2008, 82(21): 10832-10840. DOI:10.1128/jvi.00883-08.

TANNOUS B A, KIM D E, FERNANDEZ J L, et al . Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo[J ] . Mol Ther, 2005, 11(3): 435-443. DOI:10.1016/j.ymthe.2004.10.016.

BOSCO B, DEFANT A, MESSINA A, et al . Synthesis of 2, 6-diamino-substituted purine derivatives and evaluation of cell cycle arrest in breast and colorectal cancer cells[J ] . Molecules, 2018, 23(8): 1996. DOI: 10.3390/molecules23081996.

CHENG L, WANG H, GUO K C, et al . Reversine, a substituted purine, exerts an inhibitive effect on human renal carcinoma cells via induction of cell apoptosis and polyploidy[J ] . Oncotargets Ther, 2018, 11: 1025-1035. DOI:10.2147/OTT.S158198.

LU Y C, LEE Y R, LIAO J D, et al . Reversine induced multinucleated cells, cell apoptosis and autophagy in human non-small cell lung cancer cells[J ] . PLoS One, 2016, 11(7): e0158587. DOI:10.1371/journal.pone.0158587.

PICCOLI M, GHIROLDI A, MONASKY M M, et al . Reversine: a synthetic purine with a dual activity as a cell dedifferentiating agent and a selective anticancer drug[J ] . Curr Med Chem, 2020, 27(21): 3448-3462. DOI:10.2174/0929867326666190103120725.

KALKERI R, PENG J Z, HUANG C S, et al . HBV core promoter inhibition by tubulin polymerization inhibitor (SRI-32007)[J ] . Adv Virol, 2020, 2020: 8844061. DOI:10.1155/2020/8844061.

WAHLI W, MICHALIK L. PPARs at the crossroads of lipid signaling and inflammation[J]. Trends Endocrinol Metab, 2012, 23(7): 351-363. DOI: 10.1016/j.tem.2012.05.001.

TURTON K L, MEIER-STEPHENSON V, BADMALIA M D, et al . Host transcription factors in hepatitis B virus RNA synthesis[J ] . Viruses, 2020, 12(2): 160. DOI: 10.3390/v12020160.

GEHRING A J, PROTZER U. Targeting innate and adaptive immune responses to cure chronic HBV infection[J]. Gastroenterology, 2019, 156(2): 325-337. DOI:10.1053/j.gastro.2018.10.032.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Establishment of skin photoaging model and preliminary mechanism of senescence in keratinocytes cell line HaCaT

Establishment of a Burkholderia thailandensis invaded RAW264.7 cell model and underlying mechanism of infection

Establishment of a Burkholderia pseudomallei invaded A549 cell model

Construction and identification of endothelial cell model with overexpressed human protein kinase Cβ₂ induced by high glucose

Establishment of an enterohemorrhagic Escherichia coli O157∶H7 attached HeLa cell model

Related Author

Aijun CHEN

Yiyi LIU

Di CAO

Yun PAN

Ping WANG

Xin HUANG

Chuan LIU

鲁卫平

Related Institution

Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University

College of Traditional Chinese Medicine, Chongqing Medical University

⁰